Company Filing History:
Years Active: 2002
Title: The Innovations of Gary C. Starling: A Pioneer in Monoclonal Antibodies
Introduction: Gary C. Starling, an innovative inventor based in Lawrenceville, NJ, is recognized for his contributions to the field of immunology through his groundbreaking patent. His research primarily focuses on the properties and applications of monoclonal antibodies, particularly in the treatment of inflammatory and autoimmune diseases.
Latest Patents: Gary C. Starling holds one significant patent titled "Monoclonal antibodies to human CD6." This invention provides antibodies that specifically bind to the SRCR domains of human CD6 (hCD6), showcasing advantageous properties. The binding agents developed through this invention are notable for their ability to substantially inhibit the binding of activated leukocyte adhesion molecule (ALCAM) to hCD6. This innovation has far-reaching implications, particularly in the screening of peptides and drugs that interact with hCD6 and/or modulate ALCAM binding, as well as in diagnostic and therapeutic applications for managing inflammatory and autoimmune diseases.
Career Highlights: Gary currently works at Bristol-Myers Squibb Company, a leading global biopharmaceutical company. His role involves advancing research in monoclonal antibodies and contributing to the development of therapies that address critical health challenges.
Collaborations: Throughout his career, Gary has worked alongside esteemed colleagues, including Anthony W. Siadak and Michael A. Bowen. Their collaborative efforts have played a crucial role in the advancement of research in immunology and the development of innovative therapeutic strategies.
Conclusion: Gary C. Starling's work and patent are valuable contributions to the scientific community. His efforts in developing monoclonal antibodies demonstrate the potential for innovation in addressing health issues related to inflammation and autoimmune disorders. As he continues to advance research in this important field, his impact will be felt in both therapeutic applications and scientific advancements.